On the evening of May 25, China Securities Regulatory Commission (CSRC) announced that the listing committee of science and technology innovation board approved the IPO application of Vazyme Biotech Co., Ltd. According to the prospectus, Vazyme plans to raise 1.2 billion yuan, which will be used for the company's headquarters and a new research and development base, the expansion of its marketing network and the replenishment of working capital.

The number of shares issued this time will not exceed 40.01 million shares and will not be less than 10% of the total number of shares after the issuance is completed. Once the issuance is successful, it will at least be a pharmaceutical company with a market of more than 10 billion.

Founded in 2012, Vazyme is headquartered in Nanjing, Jiangsu Province. It is a biotechnology company that conducts technology research and product development on functional proteins such as enzymes, antigens, antibodies, and polymer organic materials. Relying on the key commonality of independent establishment technology platform, Vazyme has successively entered the fields of biological reagents and in vitro diagnostics, and is conducting research and development of antibody drugs. It is one of the few domestic R&D and innovative enterprises that have both independent and controllable upstream technology development capabilities and terminal product production capabilities.

From January to March 2021, the company achieved operating income of 541 million yuan, an increase of 161.33% over the same period of the previous year; net profit attributable to shareholders of the parent company was 337 million yuan, an increase of 195.37% over the same period of the previous year.

From 2018 to 2020, the total operating income of the company is  170.8047 million yuan, 268.3801 million yuan, and 1564.4543 million  yuan respectively, and the net profit attributable to the shareholders of the parent company is 1,038,700  yuan, 25.794,800  yuan and 821.725,000  yuan respectively. The gross profit margin of main business was 84.78%, 84.78% and 91.55%, respectively.

During the reporting period, the company's research and development expenses were 53.0045 million yuan, 62.2966 million yuan and 125.5334 million yuan, accounting for 31.03%, 23.21% and 8.02% of the current operating income respectively.

As of December 31, 2020, the company had a total of 40 patents, including 23 invention patents and 67 Chinese medical device registration certificates.